Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S. Cadilha BL, et al. Among authors: subklewe m. Sci Adv. 2021 Jun 9;7(24):eabi5781. doi: 10.1126/sciadv.abi5781. Print 2021 Jun. Sci Adv. 2021. PMID: 34108220 Free PMC article.
Advances in cancer immunotherapy 2019 - latest trends.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Kruger S, et al. Among authors: subklewe m. J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. J Exp Clin Cancer Res. 2019. PMID: 31217020 Free PMC article. Review.
Determinants of response and resistance to CAR T cell therapy.
Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S. Lesch S, et al. Among authors: subklewe m. Semin Cancer Biol. 2020 Oct;65:80-90. doi: 10.1016/j.semcancer.2019.11.004. Epub 2019 Nov 6. Semin Cancer Biol. 2020. PMID: 31705998 Review.
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M, Koenig LM, Formisano S, Boehmer DFR, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhöfler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger FS, Rothenfusser S. Ruzicka M, et al. Among authors: subklewe m. Leukemia. 2020 Apr;34(4):1017-1026. doi: 10.1038/s41375-019-0639-x. Epub 2019 Nov 18. Leukemia. 2020. PMID: 31740809 Free PMC article.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S. Benmebarek MR, et al. Among authors: subklewe m. Leukemia. 2021 Aug;35(8):2243-2257. doi: 10.1038/s41375-020-01109-w. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414484 Free PMC article.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S. Lesch S, et al. Among authors: subklewe m. Nat Biomed Eng. 2021 Nov;5(11):1246-1260. doi: 10.1038/s41551-021-00737-6. Epub 2021 Jun 3. Nat Biomed Eng. 2021. PMID: 34083764 Free PMC article.
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S. Stock S, et al. Among authors: subklewe m. J Immunother Cancer. 2022 Jul;10(7):e005054. doi: 10.1136/jitc-2022-005054. J Immunother Cancer. 2022. PMID: 35902133 Free PMC article.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: subklewe m. Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. doi: 10.1007/s00262-023-03439-x. Epub 2023 Apr 11. Cancer Immunol Immunother. 2023. PMID: 37041225 Free PMC article.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: subklewe m. Cancer Immunol Immunother. 2023 Jul;72(7):2513-2514. doi: 10.1007/s00262-023-03457-9. Cancer Immunol Immunother. 2023. PMID: 37154851 Free PMC article. No abstract available.
198 results